Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy

Marta Spreafico, Corrado Lodigiani, Y. van Leeuwen, Denise Pizzotti, Lidia L. Rota, F. R. Rosendaal, Pier M. Mannucci, Flora Peyvandi

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Anticoagulants of the coumarin type are effective drugs for the treatment and prevention of thromboembolic diseases. However, they have a narrow therapeutic range and show inter- and intra-individual variability in dose requirement, largely conditioned by both environmental and genetic factors. Methods: This prospective study investigated, during the initial phase of acenocoumarol therapy, the effect of CYP2C9 variant alleles and VKORC1 haplotypes, single and in combination, in 220 Italians. Results: CYP2C9*3 was associated with a 25% dose reduction and an increased risk of over-anticoagulation (International Normalized Ratio [INR]> 6) on day 4. Two copies of the VKORC1*2 haplotype were associated with a 45% dose reduction and an increased risk of over-anticoagulation. Homozygosity for VKORC1*3 and VKORC1*4 was associated with an increased dose requirement and a reduced risk of over-anticoagulation. The VKORC1*3 or *4 plus CYP2C9*1 genotype combination was associated with the highest dose requirement and the lowest INR on day 4; VKORC1*2 plus CYP2C9*3 was associated with the lowest dose requirement, the highest INR and an increased risk of over-anticoagulation. Even though they spent approximately 50% of the time within the target therapeutic range, VKORC1*3 or *4 plus CYP2C9*1 carriers spent a large percentage of the remaining time below and carriers of VKORC1*2 plus CYP2C9*3 above the target range. Discussion: The determination of VKORC1*3 and VKORC1*4 haplotypes may be an important addition to CYP2C9 and VKORC1*2 genotyping to identify patients at risk of being outside the target range during initial anticoagulation with acenocoumarol.

Original languageEnglish
Pages (from-to)1237-1250
Number of pages14
JournalPharmacogenomics
Volume9
Issue number9
DOIs
Publication statusPublished - 2008

Keywords

  • Aenocoumarol
  • Anticoagulant therapy
  • Combined genotypes
  • CYP2C9
  • Dose requirement
  • INR
  • International Normalized Ratio
  • Pharmacogenetics
  • VKORC1

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy'. Together they form a unique fingerprint.

Cite this